|Bid||15.00 x 800|
|Ask||17.47 x 1200|
|Day's Range||13.50 - 18.29|
|52 Week Range||0.52 - 19.27|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.50|
Completes Successful Initial Public Offering Raising Gross Proceeds of Approximately $71.6 Million On-Track for Early 2019 Initiation of Phase 1b/2 Trial of EQ001 in Acute.
LA JOLLA, Calif., Nov. 01, 2018 -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe.
Equillium Inc. (EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the pricing of its initial public offering of 4,670,000 shares of common stock at a public offering price of $14.00 per share. All shares of common stock are being offered by Equillium. The shares are expected to begin trading on the Nasdaq Global Market on October 12, 2018 under the ticker symbol "EQ." In addition, Equillium has granted the underwriters a 30-day option to purchase up to an additional 700,500 shares of common stock at the initial public offering price.
Equillium is set to begin trading on the Nasdaq Global Market under the ticker symbol “EQ.” The Details Equillium will offer 4.6 million shares of common stock in a price range between $14 and $16 per ...